| Kurt Dieter Dittmar, MD | |
|
1607 Ygnacio Valley Rd, Walnut Creek, CA 94598-3122 | |
| (925) 939-3000 | |
| (925) 947-5286 |
| Full Name | Kurt Dieter Dittmar |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 25 Years |
| Location | 1607 Ygnacio Valley Rd, Walnut Creek, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003858697 | NPI | - | NPPES |
| 00A752320 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | A75232 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| John Muir Medical Center - Concord Campus | Concord, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - Anesthesia Pc | 3678897915 | 324 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Entity Name | University Anesthesia Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528137296 PECOS PAC ID: 2769370535 Enrollment ID: O20040304001219 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Entity Name | John Muir Trauma Physicians Billing Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093864837 PECOS PAC ID: 3476542515 Enrollment ID: O20050420001452 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Entity Name | Cep America - Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790401438 PECOS PAC ID: 3678897915 Enrollment ID: O20150115001110 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kurt Dieter Dittmar, MD Po Box 7793, San Francisco, CA 94120-7793 Ph: () - | Kurt Dieter Dittmar, MD 1607 Ygnacio Valley Rd, Walnut Creek, CA 94598-3122 Ph: (925) 939-3000 |
News Archive
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime vaccine followed by a BNT162b2 boost vaccine after a 56-day interval due to changing vaccine recommendations in Germany. There were 16 females and 10 males in the cohort, and they were assessed for immune responses, reactogenicity, and T cell reactivity. This study is published on the medRxiv* preprint server.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis.
Scientists are reporting development of a fast, reliable new test that could help people avoid a terrible type of food poisoning that comes from eating fish tainted with a difficult-to-detect toxin from marine algae growing in warm waters. The report appears in ACS' journal Analytical Chemistry.
A revealing study published in Epilepsy & Behavior provides evidence that the perception of epilepsy is not faring well in social media. Kate McNeil and colleagues from Dalhousie University in Canada analyzed data collected from Twitter to provide a snapshot of how epilepsy is portrayed within the twitter community.
› Verified 4 days ago
Kevin George Kaiser, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 Fax: 925-947-5286 | |
David Curtis Fitzgerald, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 Fax: 925-947-5286 | |
Christine E. Sands, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
David Aaron Shapiro, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 Fax: 925-947-5286 | |
Nitin Kumar, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Mark D. Piehler, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 |